23:20 , Mar 1, 2018 |  BC Innovations  |  Targets & Mechanisms

Checking out the microbiome

What started out as a potential use in stratifying patients is growing into a new avenue for turning non-responders to responders, as evidence continues to emerge linking the microbiome to immuno-oncology. While the data are...
07:00 , May 25, 2015 |  BC Week In Review  |  Clinical News

MicOryx: Additional Phase I/IIa data

Oryx said 1 heavily pretreated patient with bulky metastases who received MicOryx in an open-label, German Phase I/IIa trial achieved stable disease. The trial enrolled 22 patients with advanced MSI-H colorectal cancer who received standard...
07:00 , Mar 16, 2015 |  BC Week In Review  |  Clinical News

MicOryx: Phase I/IIa data

An open-label Phase I/IIa trial in 22 patients with advanced MSI-H colorectal cancer who received standard chemotherapy showed that MicOryx was safe and induced humoral and cellular immune responses. Oryx GmbH & Co. KG ,...
08:00 , Jan 29, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Viral infection; lupus Hematopoietic interferon-inducible nuclear proteins with a 200-amino-acid repeat (HIN-200) gene family; tumor protein p53 binding protein 1...